- Home
- SSY vs TOVX Comparison
SSY vs TOVX Comparison
Compare SSY & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSY
- TOVX
- Stock Information
- Founded
- SSY 1959
- TOVX 2001
- Country
- SSY United States
- TOVX United States
- Employees
- SSY N/A
- TOVX N/A
- Industry
- SSY Hospital/Nursing Management
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SSY Health Care
- TOVX Health Care
- Exchange
- SSY Nasdaq
- TOVX Nasdaq
- Market Cap
- SSY 5.5M
- TOVX 4.7M
- IPO Year
- SSY N/A
- TOVX 2006
- Fundamental
- Price
- SSY $1.00
- TOVX $1.18
- Analyst Decision
- SSY
- TOVX Strong Buy
- Analyst Count
- SSY 0
- TOVX 1
- Target Price
- SSY N/A
- TOVX $6.00
- AVG Volume (30 Days)
- SSY 32.0K
- TOVX 23.1K
- Earning Date
- SSY 05-14-2025
- TOVX 05-06-2025
- Dividend Yield
- SSY N/A
- TOVX N/A
- EPS Growth
- SSY N/A
- TOVX N/A
- EPS
- SSY 0.14
- TOVX N/A
- Revenue
- SSY $31,233,000.00
- TOVX N/A
- Revenue This Year
- SSY N/A
- TOVX N/A
- Revenue Next Year
- SSY N/A
- TOVX N/A
- P/E Ratio
- SSY $7.25
- TOVX N/A
- Revenue Growth
- SSY N/A
- TOVX N/A
- 52 Week Low
- SSY $0.53
- TOVX $1.03
- 52 Week High
- SSY $1.91
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- SSY 50.27
- TOVX 44.05
- Support Level
- SSY $0.97
- TOVX $1.08
- Resistance Level
- SSY $1.09
- TOVX $1.25
- Average True Range (ATR)
- SSY 0.08
- TOVX 0.08
- MACD
- SSY -0.00
- TOVX 0.00
- Stochastic Oscillator
- SSY 61.54
- TOVX 57.89
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.